MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义

doi:10.11904/j.issn.1002-3070.2021.03.009

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (3): 243-247.doi: 10.11904/j.issn.1002-3070.2021.03.009

MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义

王俊美¹, 潘慧卿¹, 李婧铱², 贾迪², 赵炜明³, 吕昌莲¹

1.上海健康医学院协同科研中心分子影像重点实验室(上海 201318);
2.齐齐哈尔医学院医学技术学院;
3.黑龙江中医药大学

收稿日期:2021-01-13 修回日期:2021-05-06 出版日期:2021-06-28 发布日期:2021-06-22
通讯作者: 吕昌莲,E-mail:lvcl@sumhs.edu.cn
作者简介:王俊美,女,(1998-),本科,从事肿瘤学的研究。
基金资助:
国家自然科学基金项目(编号:81272376,81772829)

The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma

WANG Junmei¹, PAN Huiqing¹, LI Jingyi², JIA Di², ZHAO Weiming³, LV Changlian¹

1. Shanghai Key Laboratory of Molecular Imaging,Shanghai University of Medicine & Health Sciences,Shanghai 201318,China;
2. Medical Technology School of Qiqihar Medical University;
3. Heilongjiang University of Traditional Chinese Medicine

Received:2021-01-13 Revised:2021-05-06 Online:2021-06-28 Published:2021-06-22

摘要/Abstract

摘要： 目的探讨MT2-MMP在肺腺癌患者组织中的表达情况及其临床意义。方法收集40例病理TNM分期Ⅱ期的肺腺癌组织标本,其癌旁正常组织为对照组,进行HE染色,免疫组织化学方法检测MT2-MMP的表达进行半定量分析;应用卡方检验分析MT2-MMP表达与临床病理特征的关系;结合TCGA肺腺癌数据分析MT2-MMP在肺腺癌中的表达情况。结果肺腺癌组织呈现明显的肿瘤无序增殖病理特征;MT2-MMP在肺腺癌中表达高于癌旁正常组织,差异具有统计学意义(P＜0.001);肺腺癌组织中的MT2-MMP的表达水平与患者的肿瘤大小有关(P＜0.01),而与性别、年龄、是否有淋巴转移无明显相关(P＞0.05);TCGA大数据分析结果显示肺腺癌Ⅱ期及其他各期MT2-MMP的表达均显著高于正常组织,差异具有统计学意义(P＜0.01)。结论 MT2-MMP在Ⅱ期肺腺癌组织中呈高表达,可能参与肺腺癌早期的恶性进展,对肺腺癌的早期诊断具有潜在价值。

关键词: 基质金属蛋白酶细胞膜锚定型2, 非小细胞肺癌, 肺腺癌

Abstract: Objective The aim of this study was to investigate the expression of MT2-MMP in lung adenocarcinoma and its clinical significance.Methods A total of 40 cases of lung adenocarcinoma with pathological TNM stage Ⅱ were collected,and the adjacent normal tissues were used as controls.Immunohistochemistry was used to detect the expression of MT2-MMP for semi-quantitative analysis.Chi-square test was used to analyze the relationship between MT2-MMP expression and clinicopathological characteristics.Combined with TCGA lung adenocarcinoma data,the expression of MT2-MMP was analyzed in lung adenocarcinoma.Results Lung adenocarcinoma tissues showed obvious pathological characteristics of disordered tumor proliferation.The expression of MT2-MMP in lung adenocarcinoma tissues was higher than that in adjacent normal tissues,and the difference was statistically significant(P＜0.001).The level of MT2-MMP in lung adenocarcinoma tissues was related to the tumor size of patients(P＜0.01),but was not significantly correlated with gender,age,presence or absence of lymphatic metastasis(P＞0.05).The TCGA data analysis results showed that the expression of MT2-MMP at the stage II of lung adenocarcinoma and other stages was significantly higher than that in normal tissues,and the difference was statistically significant(P＜0.01).Conclusion MT2-MMP is highly expressed at the stage II of lung adenocarcinoma,which may be involved in the early malignant progression of lung adenocarcinoma,and has potential value for the early diagnosis of lung adenocarcinoma.

Key words: Matrix metalloproteinase cell membrane anchoring type 2, Non-small cell lung cancer, Lung adenocarcinoma

中图分类号:

R734.2

王俊美, 潘慧卿, 李婧铱, 贾迪, 赵炜明, 吕昌莲. MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2021, 35(3): 243-247.

WANG Junmei, PAN Huiqing, LI Jingyi, JIA Di, ZHAO Weiming, LV Changlian. The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma[J]. Journal of Practical Oncology, 2021, 35(3): 243-247.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.03.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I3/243

参考文献

1 Heist RS,Engelman JA.SnapShot:Non-small cell lung cancer[J].Cancer Cell,2012,21(3):448.
2 Safranek J,Pesta M,Holubec L,et al.Expression of MMP-7,MMP-9,TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer(NSCLC)and benign pulmonary disease[J].Anticancer Res,2009,29(7):2513-2517.
3 Willis AL,Sabeh F,Li XY,et al.Extracellular matrix determinants and the regulation of cancer cell invasion stratagems[J].J Microsc,2013,251(3):250-260.
4 Cho NH,Hong KP,Hong SH,et al.MMP expression profiling in recurred stage IB lung cancer[J].Oncogene,2004,23(3):845-851.
5 Egeblad M,Werb Z.New functions for the matrix metalloproteinases in cancer progression[J].Nat Rev Cancer,2002,2(3):161-174.
6 Barbara F.Matrix metalloproteinases as valid clinical targets[J].Curr Pharm Design,2007,13(3):333-346.
7 Feinberg TY,Rowe RG,Saunders TL,et al.Functional roles of MMP14 and MMP15 in early postnatal mammary gland development[J].Development,2016,143(21):3956-3968.
8 Reimar A,Juliane S,Mike R,et al.Identification of MMP-15 as an anti-apoptotic factor in cancer cells[J].J Biol Chem,2005,280(40):34123-34132.
9 Xu X,Chen L,Xu B,et al.Increased MT2-MMP expression in gastric cancer patients is associated with poor prognosis[J].Int J Clin Exp Pathol,2015,8(2):1985-1990.
10 Chen L,DI D,Luo G,et al.Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer[J].Anticancer Res,2010,30(10):4363-4368.
11 Chen L,Zhou Q,Xu B,et al.MT2-MMP expression associates with tumor progression and angiogenesis in human lung cancer[J].Int J Clin Exp Pathol,2014,7(6):3469-3477.
12 Ota I,Li XY,Hu Y,et al.Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1[J].P Natl Acad Sci,2009,106(48):20318-20323.
13 He W,Zhang H,Wang Y,et al.CTHRC1 induces non-small cell lung cancer(NSCLC)invasion through upregulating MMP-7/MMP-9[J].BMC Cancer,2018,18(1):400.
14 Liu JF,Lee CW,Tsai MH,et al.Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells[J].Biochem Pharmacol,2018,155:537-546.
15 Zupa A,Improta G,Silvestri A,et al.A pilot characterization of human lung NSCLC by protein pathway activation mapping[J].J Thorac Oncol,2012,7(12):1755-1766.
16 Schveigert D,Cicenas S,Bruzas S,et al.The value of MMP-9 for breast and non-small cell lung cancer patients′ survival[J].Adv Med Sci,2013,58(1):73-82.
17 Liu Y,Sun X,Feng J,et al.MT2-MMP induces proteolysis and leads to EMT in carcinomas[J].Oncotarget,2016,7(30):48193-48205.
18 Turunen SP,Tatti-Bugaeva O,Lehti K.Membrane-type matrix metalloproteases as diverse effectors of cancer progression.Biochim Biophys Acta Mol Cell Res,2017,1864(11 Pt A):1974-1988.
19 d′Ortho-MP,Will H,Atkinson S,et al.Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases[J].Eur J Biochem,1997,250(3):751-757.
20 Benson CS,Babu SD,Radhakrishna S,et al.Expression of matrix metalloproteinases in human breast cancer tissues[J].Dis Markers,2013,34(6):395-405.
21 Sena P,Mariani F,Marzona L,et al.Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages[J].Int J Oncol,2012,41(1):260-266.
22 Wu Y,Pan S,Leng J,et al.The prognostic value of matrix metalloproteinase-7 and matrix metalloproteinase-15 in acute myeloid leukemia[J].Cell Biochem,2019,120(6):10613-10624.
23 Hotary K,Allen E,Punturieri A,et al.Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1,2,and 3[J].J Cell Sci,2000,149(6):1309-1323.
24 Emiko I,Ikuo Y,Chisato F,et al.The role of MT2-MMP in cancer progression[J].Biochem Bioph Res Co,2010,393(2):4A-12A.
25 Tao G,Levay AK,Gridley T,et al.Mmp15 is a direct target of Snai1 during endothelial to mesenchymal transformation and endocardial cushion development[J].Dev Biol,2011,359(2):209-221.
26 Gómez-Escudero J,Moreno V,Martín-Alonso M,et al.E-cadherin cleavage by MT2-MMP regulates apical junctional signaling and epithelial homeostasis in the intestine[J].J Cell Sci,2017,130(23):4013-4027.
27 Kobayashi K,Nishioka M,Kohno T,et al.Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo[J].Oncogene,2004,23(17):3089-3096.

[1]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[2]	董程(综述),段勇(审校). Dickkopf家族蛋白在非小细胞肺癌中的作用机制和治疗应用的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 64-68.
[3]	闫䶮, 侯利芳, 李任飞, 闫鹏, 王月东, 郑玉婷. ^99mTc-HYNIC-MPG在体非小细胞肺癌分子分型研究[J]. 实用肿瘤学杂志, 2020, 34(5): 412-417.
[4]	孙亚娟, 姜智允, 尚乃舰, 孙庆鑫, 陆佩欧. 双源CT能量成像在评估非小细胞肺癌纵隔淋巴结转移中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(6): 531-535.
[5]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[6]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[7]	卞秀森, 李光, 关欣宇, 张伊, 狄畅, 马璨. UHRF1通过调控细胞自噬抑制肺腺癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 498-502.
[8]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[9]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[10]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[11]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[12]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[13]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[14]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[15]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.

MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义

The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价